Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov;12(11):646-653.
doi: 10.1038/nrendo.2016.110. Epub 2016 Jul 15.

The changing incidence of thyroid cancer

Affiliations
Review

The changing incidence of thyroid cancer

Cari M Kitahara et al. Nat Rev Endocrinol. 2016 Nov.

Abstract

During the past few decades, the incidence of thyroid cancer has increased substantially in many countries, including the USA. The rise in incidence seems to be attributable both to the growing use of diagnostic imaging and fine-needle aspiration biopsy, which has led to enhanced detection and diagnosis of subclinical thyroid cancers, and environmental factors. The latest American Thyroid Association (ATA) practice guidelines for the management of adult patients with thyroid nodules and differentiated thyroid cancer differ substantially from the previous ATA guidelines published in 2009. Specifically, the problems of overdiagnosis and overtreatment of a disease that is typically indolent, where treatment-related morbidity might not be justified by a survival benefit, now seem to be acknowledged. As few modifiable risk factors for thyroid cancer have been established, the specific environmental factors that have contributed to the rising incidence of thyroid cancer remain speculative. However, the findings of several large, well-designed epidemiological studies have provided new information about exposures (such as obesity) that might influence the development of thyroid cancer. In this Review, we describe the changing incidence of thyroid cancer, suggest potential explanations for these trends, emphasize the implications for patients and highlight ongoing and potential strategies to combat this growing clinical and public health issue.

PubMed Disclaimer

Conflict of interest statement

Competing interests

C.M.K. declares no competing interests. J.A.S. is on the Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry, which is sponsored by NovoNordisk, GlaxoSmithKline, Astra Zeneca and Eli Lilly.

Figures

FIG. 1 |
FIG. 1 |
Trends in total and histology-specific thyroid cancer incidence (SEER 13) and total thyroid cancer mortality (USA) from 1993–2012. Rates are age-adjusted (2000 US standard population) and each point represents 4 years. Incidence data are from the SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, Los Angeles, San Jose-Monterey and the Alaska Native Registry); thyroid cancer cases are restricted to those microscopically confirmed and exclude cases identified only by autopsy or death certificates. Mortality data are from the US Mortality Files, National Center for Health Statistics, Center for Disease Control and Prevention. Annual percent change (APC) based on rates age-adjusted to the 2000 US standard population (19 age groups – Census P25–1130). *APC is significantly different from zero (P <0.05).

References

    1. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; (2013). Available from: http://globocan.iarc.fr, accessed on 5/6/2016.
    1. Ron E, Schneider AB in Cancer Epidemiology and Prevention (ed. Schottenfeld D, Fraumeni JF Jr.) (Oxford University Press, 2006). Chapter 50, pp 975–94.
    1. Kilfoy BA et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 20, 525–31 (2009). - PMC - PubMed
    2. Increases in the incidence of thyroid cancer were found in most of the countries with available, high-quality registry data, and no differences were observed by region of the world or underlying thyroid cancer rates.

    1. Enewold L et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18, 784–91 (2009). - PMC - PubMed
    2. This comprehensive descriptive analysis of thyroid cancer trends in the U.S. described increases in incidence of papillary thyroid cancer of all stages and sizes at diagnosis, including similar rates of increase for large (>5 cm) and small (≤1 cm) tumors, suggesting that medical surveillance cannot completely explain these patterns.

    1. Kent WD et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177, 1357–61 (2007). - PMC - PubMed
    2. Pathology reports obtained from the Ontario Cancer Registry showed an increasing incidence of differentiated thyroid cancer and a disproportionate increase in the number of smaller (≤ 2cm) versus larger tumors between 1990 and 2001.

MeSH terms

Supplementary concepts